Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and/or females between the ages of ≥18 and ≤70 years at Screening~2. Patients in whom T2DM has been diagnosed according to 1999 WHOT2DM diagnostic criteria~3. HbA1c ≥7.5% and ≤11% at Screening and at Week -1~4. Body mass index (BMI) ≥18.5 and ≤35.0 kg/m2 at Screening~Exclusion Criteria:~1. Female who is pregnant, intends to become pregnant or breast-feeding or is of child-bearing potential and not using adequate contraception methods throughout the trial~2. Treatment with any glucose lowing agent(s) within 3 months prior to screening.An exception is short-term treatment (no longer than 7 days in total) with insulin in connection with inter-current illness~3. Calcitonin ≥50 ng/L at screening~4. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia, type 2~5. Fasting triglyceride ≥500 mg/dL at Screening, or patients with a history of lipid disorders taking unstable treatment dosage (eg, statins) within 3 months prior to screening~6. Any acute or chronic condition that, in the opinion of the Investigator, would limit the patient's ability to complete and/or participate in this trial~7. Blood amylase or lipase \>3x ULN, history of acute or chronic pancreatitis, or history of symptomatic gallbladder disease at Screening~8. Serum creatinine ≥1.5 mg/dL (male patients) or ≥1.4 mg/dL (female patients), or estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m2 at Screening~9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2x upper limit of normal (ULN) at Screening and pre-randomization~10. Severe cardiovascular diseases occurring within 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PB-119 75ug (Type: EXPERIMENTAL): PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
- PB-119 150ug (Type: EXPERIMENTAL): PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
- PB-119 200ug (Type: EXPERIMENTAL): PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo injection subcutaneously injected once-weekly for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).